Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Armata Pharmaceuticals Inc is a clinical-stage biotechnology company focused on improving human health through the development of novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious diseases of the microbiome. The company is developing and advancing lead clinical phage candidate for Pseudomonas aeruginosa (P. aeruginosa), AP-PA02. It is also focused on developing a phage product candidate for Staphylococcus aureus (S. aureus) for the treatment of S. aureus bacteremia, AP-SA02.
Marina del Rey, CA, 90292